Lindus Health has raised $18m in a Series A funding round to scale up and continue executing its end-to-end clinical trials.

Led by Creandum, the funding round also involved participation from PayPal co-founder Peter Thiel and returning investors Hambro Perks, firstminute, Seedcamp, Amino Collective, Calm/Storm and Page One Ventures.

Angel investors, including Kaysan Nikkhah, Nadav Rosenberg, Trevor Martin, Andrej Steinberg, Soraya Darabi, Tom Krüger and Mithi Thaya, also provided funding.

Lindus Health has already delivered more than 80 clinical trials across the UK, the US, and Europe and is planning to launch studies for menopause, insomnia, tinnitus, and childhood myopia treatments.

The latest funding will enable the company to expand its technology platform for delivering additional end-to-end trials and quality data to research sponsors.

Lindus Health co-founder Michael Young said: “Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Through this latest raise, we will be further investing in our technology platform so that we can deliver clinical trials in completely new ways.”

The company uses its technology platform for executing trials from beginning to completion.

This gives patients access to treatments quickly to improve and extend the lives of those with chronic illnesses.

Creandum general partner Fredrik Cassel said: “With a tech-first, AI-powered, end-to-end offering, Lindus Health is building unparalleled efficiency and quality into what has always been a manual process.”